Abbott Historical Balance Sheet
ABT Stock | USD 103.95 0.28 0.27% |
Trend analysis of Abbott Laboratories balance sheet accounts such as Short Long Term Debt Total of 9.8 B, Other Current Liabilities of 8.1 B or Total Current Liabilities of 8.3 B provides information on Abbott Laboratories' total assets, liabilities, and equity, which is the actual value of Abbott Laboratories to its prevalent stockholders. By breaking down trends over time using Abbott Laboratories balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Abbott Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Abbott Laboratories is a good buy for the upcoming year.
Abbott Laboratories Inventory |
|
Abbott |
About Abbott Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Abbott Laboratories at a specified time, usually calculated after every quarter, six months, or one year. Abbott Laboratories Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Abbott Laboratories and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Abbott currently owns. An asset can also be divided into two categories, current and non-current.
Abbott Laboratories Balance Sheet Chart
Abbott Laboratories Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Abbott Laboratories uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Abbott Laboratories' Common Stock Total Equity is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 757.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Abbott Laboratories balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Abbott Laboratories are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Accounts Payable
An accounting item on the balance sheet that represents Abbott Laboratories obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Abbott Laboratories are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Good Will
An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.Most accounts from Abbott Laboratories' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Abbott Laboratories current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.At this time, Abbott Laboratories' Common Stock Total Equity is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 757.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 19.0B | 17.7B | 15.9B | 9.8B | Total Assets | 75.2B | 74.4B | 73.2B | 36.9B |
Abbott Laboratories balance sheet Correlations
Click cells to compare fundamentals
Abbott Laboratories Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Abbott Laboratories balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 67.9B | 72.5B | 75.2B | 74.4B | 73.2B | 36.9B | |
Short Long Term Debt Total | 18.9B | 19.6B | 19.0B | 17.7B | 15.9B | 9.8B | |
Other Current Liab | 6.1B | 7.7B | 7.9B | 8.6B | 7.7B | 8.1B | |
Total Current Liabilities | 10.9B | 11.9B | 13.1B | 15.5B | 13.8B | 8.3B | |
Total Stockholder Equity | 31.1B | 32.8B | 35.8B | 36.7B | 38.6B | 40.5B | |
Property Plant And Equipment Net | 8.0B | 9.0B | 9.0B | 9.2B | 11.3B | 6.2B | |
Net Debt | 15.0B | 12.8B | 9.2B | 7.8B | 9.0B | 6.1B | |
Retained Earnings | 25.8B | 27.6B | 31.5B | 35.3B | 37.6B | 39.4B | |
Cash | 3.9B | 6.8B | 9.8B | 9.9B | 6.9B | 3.7B | |
Non Current Assets Total | 52.2B | 52.1B | 51.0B | 49.2B | 50.5B | 53.1B | |
Non Currrent Assets Other | 52.2B | 3.7B | 5.2B | 6.0B | 6.0B | 3.0B | |
Cash And Short Term Investments | 4.1B | 7.1B | 10.2B | 10.2B | 7.3B | 4.3B | |
Net Receivables | 5.4B | 6.4B | 6.5B | 8.9B | 6.6B | 3.9B | |
Common Stock Shares Outstanding | 1.8B | 1.8B | 1.8B | 1.8B | 1.8B | 1.3B | |
Liabilities And Stockholders Equity | 67.9B | 72.5B | 75.2B | 74.4B | 73.2B | 36.9B | |
Non Current Liabilities Total | 25.7B | 27.6B | 26.1B | 22.0B | 20.5B | 11.7B | |
Inventory | 4.3B | 5.0B | 5.2B | 6.2B | 6.6B | 6.9B | |
Other Current Assets | 1.8B | 1.9B | 2.3B | 2.7B | 2.3B | 2.2B | |
Other Stockholder Equity | (10.1B) | (10.0B) | (11.8B) | (15.2B) | (16.0B) | (16.8B) | |
Total Liab | 36.6B | 39.5B | 39.2B | 37.5B | 34.4B | 20.0B | |
Property Plant And Equipment Gross | 8.0B | 9.0B | 19.4B | 20.2B | 21.9B | 23.0B | |
Total Current Assets | 15.7B | 20.4B | 24.2B | 25.2B | 22.7B | 13.3B | |
Accumulated Other Comprehensive Income | (8.5B) | (8.9B) | (8.4B) | (8.1B) | (7.8B) | (7.4B) | |
Short Term Debt | 207M | 1.5B | 220M | 754M | 2.3B | 2.0B | |
Accounts Payable | 3.3B | 3.9B | 4.4B | 4.6B | 4.3B | 4.5B | |
Common Stock Total Equity | 23.9B | 24.1B | 24.5B | 24.7B | 28.4B | 29.8B | |
Short Term Investments | 280M | 310M | 450M | 288M | 383M | 757.2M | |
Common Stock | 23.9B | 24.1B | 24.5B | 24.7B | 24.9B | 23.6B | |
Intangible Assets | 17.0B | 14.8B | 12.7B | 10.5B | 8.8B | 9.1B | |
Other Liab | 8.3B | 8.2B | 7.8B | 6.6B | 7.6B | 5.7B | |
Other Assets | 2.4B | 2.8B | 4.1B | 4.9B | 5.7B | 5.9B | |
Long Term Debt | 16.7B | 18.5B | 17.3B | 14.5B | 13.6B | 12.0B | |
Treasury Stock | (10.0B) | (10.1B) | (10.0B) | (11.8B) | (10.6B) | (10.1B) | |
Property Plant Equipment | 8.0B | 9.0B | 9.0B | 9.2B | 10.5B | 7.7B | |
Good Will | 23.2B | 23.7B | 23.2B | 22.8B | 23.7B | 15.5B | |
Net Tangible Assets | (70M) | 3.4B | (2.2B) | 11.0B | 9.9B | 10.4B | |
Noncontrolling Interest In Consolidated Entity | 198M | 213M | 219M | 222M | 251.9M | 163.8M | |
Retained Earnings Total Equity | 25.8B | 27.6B | 31.5B | 35.3B | 40.5B | 27.2B | |
Long Term Debt Total | 16.7B | 18.5B | 17.3B | 14.5B | 16.7B | 15.8B |
Pair Trading with Abbott Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.Moving together with Abbott Stock
0.87 | DH | Definitive Healthcare | PairCorr |
0.66 | DOCS | Doximity | PairCorr |
0.77 | VEEV | Veeva Systems Class Earnings Call This Week | PairCorr |
0.82 | ENSG | Ensign Group | PairCorr |
0.79 | FEMY | Femasys | PairCorr |
Moving against Abbott Stock
0.85 | EHC | Encompass Health Corp | PairCorr |
0.72 | WGS | GeneDx Holdings Corp | PairCorr |
0.71 | CYH | Community Health Systems | PairCorr |
0.71 | GCTK | GlucoTrack | PairCorr |
0.7 | THC | Tenet Healthcare | PairCorr |
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Abbott Stock analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 2.12 | Earnings Share 3.21 | Revenue Per Share 23.181 | Quarterly Revenue Growth 0.022 |
The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.